RECURRENT NON-SMALL CELL LUNG CARCINOMA
Clinical trials for RECURRENT NON-SMALL CELL LUNG CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT NON-SMALL CELL LUNG CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT NON-SMALL CELL LUNG CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a diabetes drug boost lung cancer treatment?
Disease control CompletedThis study looked at whether adding metformin (a common diabetes medicine) to standard chemotherapy and radiation helps people with stage III non-small cell lung cancer live longer without their cancer getting worse. About 170 adults with advanced lung cancer took part. The goal …
Matched conditions: RECURRENT NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Lung cancer combo fails to outperform standard pill
Disease control CompletedThis study tested whether adding cetuximab (an antibody) to afatinib (a targeted pill) helps people with advanced EGFR-mutant lung cancer live longer. 174 patients were randomly assigned to receive either the combination or afatinib alone. The results showed no significant improv…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo therapy shows promise for hard-to-treat lung cancer
Disease control CompletedThis study tested a combination of a cancer vaccine (TG4010) and an immunotherapy drug (nivolumab) in 13 people with advanced non-small cell lung cancer who had already received other treatments. The goal was to see if the combination could shrink tumors or stop them from growing…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—sEphB4-HSA and pembrolizumab—in 42 people with advanced non-small cell lung cancer or head & neck cancer that had spread or returned. The goal was to see if the combo could shrink tumors better than standard treatments. Participants ha…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Old arthritis drug paired with immune suppressant shows promise against tough lung cancers
Disease control CompletedThis study tested two drugs—auranofin (originally for arthritis) and sirolimus (an immune suppressant)—in 29 people with advanced or recurrent lung cancer who had no standard options left. The goal was to find the safest dose and see if the combination could slow cancer growth. T…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 26, 2026 13:58 UTC
-
New radiation approach targets multiple tumors at once in early trial
Knowledge-focused CompletedThis early-phase trial tested a precise, high-dose radiation technique called stereotactic body radiotherapy (SBRT) in 42 patients with breast, lung, or prostate cancer that had spread to several places in the body. The main goal was to find the safest dose and check for side eff…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC